Alto Neuroscience/$ANRO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alto Neuroscience
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
- Ticker
- $ANRO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 68
- Headquarters
- Mountain View, United States
- Website
- www.altoneuroscience.com
ANRO Metrics
BasicAdvanced
$888M
-
-$2.38
1.16
-
Price and volume
Market cap
$888M
Beta
1.16
52-week high
$37.48
52-week low
$5.71
Average daily volume
645K
Financial strength
Current ratio
14.852
Quick ratio
14.637
Long term debt to equity
0.083
Total debt to equity
0.106
Interest coverage (TTM)
-39.04%
Profitability
EBITDA (TTM)
-87.584
Management effectiveness
Return on assets (TTM)
-26.79%
Return on equity (TTM)
-49.17%
Valuation
Price to book
3.62
Price to tangible book (TTM)
3.62
Price to free cash flow (TTM)
-11.635
Free cash flow yield (TTM)
-8.59%
Free cash flow per share (TTM)
-1.944
Growth
Earnings per share change (TTM)
-1.06%
What the Analysts think about ANRO
Analyst ratings (Buy, Hold, Sell) for Alto Neuroscience stock.
Analyst projections of the future price of Alto Neuroscience stock.
Bulls say / Bears say
ALTO-207 has a promising clinical signal: its Phase 2a study showed a statistically significant improvement in depression symptoms, with a Cohen’s d of 1.1. Alto has now started a larger Phase 2b trial in treatment-resistant depression, supported by positive external evidence for pramipexole augmentation. (Business Wire, Business Wire)
Alto has strengthened its funding position. It reported about $264 million in cash at 31 March 2026 and said this should fund the ALTO-207 Phase 2b and planned Phase 3 programmes, as well as other pipeline readouts, through 2029. (Business Wire)
Investors are not relying on one programme alone. ALTO-300 and ALTO-100 are both in Phase 2b trials, with topline results guided for the first half and middle of 2027 respectively, creating additional potential value catalysts in major depressive disorder and bipolar depression. (Business Wire)
The ALTO-101 schizophrenia programme failed to reach statistical significance on its primary EEG outcome. Alto does not plan to advance it independently and is instead seeking a partner, reducing the near-term value of that part of the pipeline. (Business Wire, Business Wire)
ALTO-207 still carries meaningful validation and tolerability risk. Its encouraging Phase 2a evidence came from only 32 patients, treatment-related nausea affected 15% during maintenance, and the larger Phase 2b readout is not expected until the second half of 2027. (Business Wire, Business Wire)
The company is still dependent on equity funding while it develops unapproved medicines. In July, Alto raised $100 million by issuing 3.78 million shares, which funds ALTO-207 but also dilutes existing shareholders and highlights the cost of advancing the pipeline. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
ANRO Financial Performance
Revenues and expenses
ANRO Earnings Performance
Company profitability
Upcoming events
No upcoming events
ANRO News
AllArticlesVideos
Funds containing ANRO
AllEURGBPUSD
Fund name | Fund size | $ANRO weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.02% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.